IQVIA Holdings Inc. $IQV Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 3.2% during the first quarter, Holdings Channel reports. The institutional investor owned 951,484 shares of the medical research company’s stock after selling 31,952 shares during the period. Bank of New York Mellon Corp’s holdings in IQVIA were worth $162,266,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sanctuary Advisors LLC raised its holdings in IQVIA by 10.8% during the first quarter. Sanctuary Advisors LLC now owns 16,216 shares of the medical research company’s stock worth $2,765,000 after purchasing an additional 1,576 shares in the last quarter. Camden National Bank boosted its holdings in shares of IQVIA by 10.9% in the 1st quarter. Camden National Bank now owns 1,244 shares of the medical research company’s stock valued at $212,000 after buying an additional 122 shares in the last quarter. Checchi Capital Advisers LLC boosted its holdings in shares of IQVIA by 24.6% in the 1st quarter. Checchi Capital Advisers LLC now owns 1,615 shares of the medical research company’s stock valued at $275,000 after buying an additional 319 shares in the last quarter. Hillsdale Investment Management Inc. grew its position in shares of IQVIA by 6,125.0% in the 1st quarter. Hillsdale Investment Management Inc. now owns 4,980 shares of the medical research company’s stock valued at $849,000 after buying an additional 4,900 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in IQVIA by 43.8% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 2,677 shares of the medical research company’s stock worth $457,000 after acquiring an additional 815 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Evercore reaffirmed an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Mizuho upped their target price on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. HSBC reaffirmed a “buy” rating and set a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Finally, Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $225.71.

IQVIA Stock Performance

Shares of IQV opened at $206.26 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm’s 50-day moving average is $185.04 and its two-hundred day moving average is $187.88. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $247.04. The firm has a market capitalization of $34.42 billion, a P/E ratio of 25.56, a PEG ratio of 1.85 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the firm posted $2.70 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.